Ultra–low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma
Correction(s) for this article
-
Ultra–low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma
- Chelsea C. Pinnix MD, PhD,
- Bouthaina S. Dabaja MD,
- Sarah A. Milgrom MD,
- Grace L. Smith MD, PhD,
- Zeinab Abou Yehia MD,
- Loretta Nastoupil MD,
- Jorge Romaguera MD,
- Francesco Turturro MD,
- Nathan Fowler MD,
- Luis Fayad MD,
- Jason Westin MD,
- Sattva Neelapu MD,
- Michelle A. Fanale MD,
- Maria A. Rodriguez MD,
- Frederick Hagemeister MD,
- Hun Ju Lee MD,
- Yasuhiro Oki MD,
- Michael Wang MD,
- Felipe Samaniego MD,
- Linda Chi MD,
- Bita Esmaeli MD,
- Volume 41Issue 5Head & Neck
- pages: 1546-1546
- First Published online: March 19, 2019
-
Ultra–low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma
- Chelsea C. Pinnix MD, PhD,
- Bouthaina S. Dabaja MD,
- Sarah A. Milgrom MD,
- Grace L. Smith MD, PhD,
- Zeinab Abou MD,
- Loretta Nastoupil MD,
- Jorge Romaguera MD,
- Francesco Turturro MD,
- Nathan Fowler MD,
- Luis Fayad MD,
- Jason Westin MD,
- Sattva Neelapu MD,
- Michelle A. Fanale MD,
- Maria A. Rodriguez MD,
- Frederick Hagemeister MD,
- Hun Ju Lee MD,
- Yasuhiro Oki MD,
- Michael Wang MD,
- Felipe Samaniego MD,
- Linda Chi MD,
- Bita Esmaeli MD,
- Volume 40Issue 6Head & Neck
- pages: 1335-1335
- First Published online: February 21, 2018
Chelsea C. Pinnix MD, PhD
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorBouthaina S. Dabaja MD
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorSarah A. Milgrom MD
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorGrace L. Smith MD, PhD
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorZeinab Abou MD
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorLoretta Nastoupil MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorJorge Romaguera MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorFrancesco Turturro MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorNathan Fowler MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorLuis Fayad MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorJason Westin MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorSattva Neelapu MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorMichelle A. Fanale MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorMaria A. Rodriguez MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorFrederick Hagemeister MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorHun Ju Lee MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorYasuhiro Oki MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorMichael Wang MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorFelipe Samaniego MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorLinda Chi MD
Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorCorresponding Author
Bita Esmaeli MD
Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
Corresponding author: B. Esmaeli, Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1488, Houston, TX 77030. E-mail: [email protected]Search for more papers by this authorChelsea C. Pinnix MD, PhD
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorBouthaina S. Dabaja MD
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorSarah A. Milgrom MD
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorGrace L. Smith MD, PhD
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorZeinab Abou MD
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorLoretta Nastoupil MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorJorge Romaguera MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorFrancesco Turturro MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorNathan Fowler MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorLuis Fayad MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorJason Westin MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorSattva Neelapu MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorMichelle A. Fanale MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorMaria A. Rodriguez MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorFrederick Hagemeister MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorHun Ju Lee MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorYasuhiro Oki MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorMichael Wang MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorFelipe Samaniego MD
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorLinda Chi MD
Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorCorresponding Author
Bita Esmaeli MD
Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
Corresponding author: B. Esmaeli, Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1488, Houston, TX 77030. E-mail: [email protected]Search for more papers by this authorThis work was presented at the American Society of Radiation Oncology 57th Annual Meeting, San Antonio, Texas, October 18–21, 2015.
This article was published online on 03 April 2017. An error was subsequently identified in Figure 2. This notice is included in the online version to indicate that Figure 2 has been corrected 14 February 2018.
ABSTRACT
Background
The purpose of this study was to report the response to and toxicity of ultra–low-dose radiotherapy (RT) for B-cell ocular adnexal lymphoma (OAL).
Methods
We conducted a retrospective review of patients with indolent B-cell and mantle cell OAL treated with 4 Gy to the orbit(s) in two 2-Gy fractions. Disease response was assessed clinically and/or radiographically at 2 to 4-month intervals after RT. Data collected included rates of overall response, complete response (CR), partial response (PR), and treatment-related toxic effects.
Results
Twenty-two patients (median age, 65 years) had the following histologic subtypes: mucosa-associated lymphoid tissue (MALT; 14 patients; 64%); follicular lymphoma (5 patients; 23%); mantle cell lymphoma (MCL; 2 patients; 9%); and unclassifiable (1 patient, 4%). The overall response rate was 100%; 19 patients (86%) had a CR and 3 patients (14%) had a PR. The only acute toxic effect was grade 1 dry eye syndrome in 1 patient.
Conclusion
Ultra–low-dose RT in patients with OAL is associated with high response rates and minimal toxic effects, and is much shorter in duration and cost. © 2017 Wiley Periodicals, Inc. Head Neck 39: 1095–1100, 2017
REFERENCES
- 1
Freeman C,
Berg JW,
Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972; 29: 252–260.
10.1002/1097-0142(197201)29:1<252::AID-CNCR2820290138>3.0.CO;2-# CAS PubMed Web of Science® Google Scholar
- 2 Margo CE, Mulla ZD. Malignant tumors of the orbit. Analysis of the Florida Cancer Registry. Ophthalmology 1998; 105: 185–190.
- 3 Ferreri AJ, Blay JY, Reni M, et al. Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 2002; 13: 531–538.
- 4 Cheah CY, Milgrom S, Chihara D, et al. Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. Neuro Oncol 2016; 18: 575–581.
- 5 Bolek TW, Moyses HM, Marcus RB Jr, et al. Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys 1999; 44: 31–36.
- 6 Pelloski CE, Wilder RB, Ha CS, Hess MA, Cabanillas FF, Cox JD. Clinical stage IEA-IIEA orbital lymphomas: outcomes in the era of modern staging and treatment. Radiother Oncol 2001; 59: 145–151.
- 7 Stafford SL, Kozelsky TF, Garrity JA, et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol 2001; 59: 139–144.
- 8 Minehan KJ, Martenson JA Jr, Garrity JA, et al. Local control and complications after radiation therapy for primary orbital lymphoma: a case for low-dose treatment. Int J Radiat Oncol Biol Phys 1991; 20: 791–796.
- 9 Goda JS, Le LW, Lapperriere NJ, et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. Int J Radiat Oncol Biol Phys 2011; 81: e659–e666.
- 10 Kennerdell JS, Flores NE, Hartsock RJ. Low-dose radiotherapy for lymphoid lesions of the orbit and ocular adnexa. Ophthal Plast Reconstr Surg 1999; 15: 129–133.
- 11 Fasola CE, Jones JC, Huang DD, Le QT, Hoppe RT, Donaldson SS. Low-dose radiation therapy (2 Gy x 2) in the treatment of orbital lymphoma. Int J Radiat Oncol Biol Phys 2013; 86: 930–935.
- 12 Nasser QJ, Pfeiffer ML, Romaguera J, et al. Clinical value of magnetic resonance imaging and other baseline testing for conjunctival mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma 2014; 55: 1013–1017.
- 13 Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059–3068.
- 14 Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176–181.
- 15 Tran KH, Campbell BA, Fua T, et al. Efficacy of low dose radiotherapy for primary orbital marginal zone lymphoma. Leuk Lymphoma 2013; 54: 491–496.
- 16 Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 2011; 100: 86–92.
- 17 Haque W, Voong KR, Shihadeh F, et al. Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients. Clin Lymphoma Myeloma Leuk 2014; 14: 474–479.
- 18 Russo AL, Chen YH, Martin NE, et al. Low-dose involved-field radiation in the treatment of non-Hodgkin lymphoma: predictors of response and treatment failure. Int J Radiat Oncol Biol Phys 2013; 86: 121–127.
- 19 Rossier C, Schick U, Miralbell R, Mirimanoff RO, Weber DC, Ozsahin M. Low-dose radiotherapy in indolent lymphoma. Int J Radiat Oncol Biol Phys 2011; 81: e1–e6.
- 20 Chan EK, Fung S, Gospodarowicz M, et al. Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011; 81: e781–e786.
- 21 Girinsky T, Guillot–Vals D, Koscielny S, et al. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys 2001; 51: 148–155.
- 22 Parikh RR, Moskowitz BK, Maher E, et al. Long-term outcomes and patterns of failure in orbital lymphoma treated with primary radiotherapy. Leuk Lymphoma 2015; 56: 1266–1270.
- 23 Le QT, Eulau SM, George TI, et al. Primary radiotherapy for localized orbital MALT lymphoma. Int J Radiat Oncol Biol Phys 2002; 52: 657–663.
- 24 Tsang RW, Gospodarowicz MK, Pintilie M, et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 2001; 50: 1258–1264.
- 25 Pinnix CC, Reed V, Dabaja B. Gastric MALT lymphoma treated with primary radiotherapy in the setting of autoimmune disease. J Natl Compr Canc Netw 2012; 10: 815–819.
- 26 Voulgarelis M, Ziakas PD, Papageorgiou A, Baimpa E, Tzioufas AG, Moutsopoulos HM. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren Syndrome. Medicine (Baltimore) 2012; 91: 1–9.
- 27 Tonami H, Matoba M, Kuginuki Y, et al. Clinical and imaging findings of lymphoma in patients with Sjögren syndrome. J Comput Assist Tomogr 2003; 27: 517–524.
Citing Literature
